Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Biodegradable in-situ forming implants and methods of producing the same|
|Abstract:||A biodegradable polymer is provided for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. The polymer is placed into the animal in liquid form and cures to form the implant in-situ. A thermoplastic system to form said implant comprises the steps of dissolving a non-reactive polymer in biocompatible solvent to form a liquid, placing the liquid within the animal, and allowing the solvent to dissipate to produce the implant. An alternative, thermosetting system comprises mixing together effective amounts of a liquid acrylic ester terminated, biodegradable prepolymer and a curing agent, placing the liquid mixture within an animal and allowing the prepolymer to cure to form the implant. Both systems provide a syringeable, solid biodegradable delivery system by the addition of an effective level of biologically active agent to the liquid before injection into the body.|
|Inventor(s):||Dunn; Richard L. (Fort Collins, CO), English; James P. (Birmingham, AL), Cowsar; Donald R. (Birmingham, AL), Vanderbilt; David D. (Birmingham, AL)|
|Assignee:||Atrix Laboratories, Inc. (Fort Collins, CO)|
|Filing Date:||Dec 23, 1991|
|Claims:||1. A pharmaceutical composition for forming a biodegradable pharmaceutically acceptable implant in-situ within a living body, comprising an effective amount of a pharmaceutically acceptable liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and a residue of an oligomer having terminal functional groups capable of reacting with acryloyl acylating groups wherein the prepolymer is capable of being cured into said implant in-situ within a living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically antalyzed hydrolysis; and an effective amount of a pharmaceutically acceptable curing agent. |
2. The composition of claim 1, wherein said liquid acrylic ester terminated prepolymer is a product of a conversion of a polyol-terminated biodegradable prepolymer.
3. The composition of claim 2, wherein said polyol-terminated biodegradable prepolymer is a product of co-polymerization of DL-lactide and .epsilon.-caprolactone with a polyol initiator.
4. The composition of claim 2, wherein said polyol-terminated biodegradable prepolymer is a product of co-polymerization of L-lactide and .epsilon.-caprolactone with a polyol initiator.
5. The composition of claim 1, wherein said curing agent is azobisisbutyronitrile.
6. The composition of claim 1, wherein said curing agent is benzoyl peroxide.
7. The composition of claim 1, and further comprising an effective amount of a biologically active agent.
8. The composition of claim 1, wherein said liquid acrylic-ester-terminated prepolymer is capable of being cured into said implant in-situ within a body.
9. The composition of claim 1, further comprising a filler.
10. The composition of claim 2, wherein said polyol-terminated prepolymer is selected from the group consisting essentially of polylactides, polyglycolides, polycaprolactones, polydioxanones, polycarbonates, polyhydroxybutyrates, polyalkylene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), polyorthoesters, and copolymers, terpolymers and combinations and mixtures thereof.
11. A pharmaceutical kit suitable for in-situ formation of a biodegradable implant in a body, which comprises:
an effective amount of a liquid acrylic-ester terminated prepolymer of terminal acryloyl groups and oligomer having terminal functional groups capable of reacting with an acryloyl compound wherein the prepolymer is capable of being cured into said implant in-situ in the living body and the cured form of the prepolymer is water insoluble and is biodegradable by simple or enzymatically catalyzed hydrolysis;
an effective amount of a curing agent in a suitable form for combination with the liquid prepolymer; and,
a device for application of a liquid combination of the liquid prepolymer and curing agent, the device having a outlet for the liquid combination, an ejector for expelling the liquid combination through the outlet and a hollow tube fitted to the outlet for inserting the liquid combination into a site of the living body such that the liquid combination can form an implant in-situ at said site.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.